INmune Bio, Inc. (INMB)
1.46
-0.08
(-5.19%)
USD |
NASDAQ |
Oct 23, 16:00
1.49
+0.03
(+2.05%)
After-Hours: 20:00
INmune Bio Enterprise Value : 23.37M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 23.37M |
| October 22, 2026 | 25.58M |
| October 21, 2026 | 27.52M |
| October 20, 2026 | 27.24M |
| October 19, 2026 | 25.58M |
| October 16, 2026 | 26.41M |
| October 15, 2026 | 28.62M |
| October 14, 2026 | 27.24M |
| October 13, 2026 | 29.45M |
| October 12, 2026 | 32.22M |
| October 09, 2026 | 35.26M |
| October 08, 2026 | 33.60M |
| October 07, 2026 | 34.43M |
| October 06, 2026 | 34.71M |
| October 05, 2026 | 36.64M |
| October 02, 2026 | 36.37M |
| October 01, 2026 | 36.37M |
| September 30, 2026 | 36.92M |
| September 29, 2026 | 37.20M |
| September 28, 2026 | 38.30M |
| September 25, 2026 | 39.13M |
| September 24, 2026 | 38.30M |
| September 23, 2026 | 38.30M |
| September 22, 2026 | 42.73M |
| September 21, 2026 | 46.32M |
| Date | Value |
|---|---|
| September 18, 2026 | 47.43M |
| September 17, 2026 | 43.28M |
| September 16, 2026 | 39.68M |
| September 15, 2026 | 45.49M |
| September 14, 2026 | 47.43M |
| September 11, 2026 | 44.39M |
| September 10, 2026 | 46.87M |
| September 09, 2026 | 51.02M |
| September 08, 2026 | 52.40M |
| September 04, 2026 | 50.47M |
| September 03, 2026 | 45.77M |
| September 02, 2026 | 47.98M |
| September 01, 2026 | 44.94M |
| August 31, 2026 | 46.60M |
| August 28, 2026 | 47.43M |
| August 27, 2026 | 49.36M |
| August 26, 2026 | 50.61M |
| August 25, 2026 | 50.19M |
| August 24, 2026 | 48.26M |
| August 21, 2026 | 47.15M |
| August 20, 2026 | 42.73M |
| August 19, 2026 | 44.66M |
| August 18, 2026 | 41.34M |
| August 17, 2026 | 41.90M |
| August 14, 2026 | 43.00M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.273M |
| Total Expenses (Quarterly) | 1.273M |
| EPS Diluted (Quarterly) | -0.0476 |
| Earnings Yield | -47.42% |
| Normalized Earnings Yield | -48.51 |